Professional
Added to YB: 2024-06-05
Pitch date: 2024-06-05
ALVR [bullish]
AlloVir, Inc.
-43.96%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
As of March 18, 2025, AlloVir, Inc. was acquired by Kalaris Therapeutics, Inc., in a reverse merger transaction.
Market Cap
$49.2M
Pitch Price
$17.51
Price Target
N/A
Dividend
N/A
EV/EBITDA
1.26
P/E
-0.84
EV/Sales
N/A
Sector
Biotechnology
Category
special_situation
Show full summary:
$ALVR setup for acquisition?
$ALVR: Speculative biotech play. Stock down big, facing delisting. $165M cash, 95% workforce cut, assessing strategic options. Insider bonuses hint at potential acquisition. High risk, high reward opportunity.
Read full article (1 min)